Imaging Early Response to Checkpoint Inhibition

Immune checkpoint blockade therapy has achieved remarkable clinical success, but these promising results have been limited to a minority of patients. Thus far, efforts to establish a predictive biomarker or accurately assess early response to treatment have been fruitless. In this issue of Cancer Research, Saida and colleagues utilized advanced molecular imaging modalities to assess changes in the tumor microenvironment that correlate with tumor response to immune checkpoint blockade therapy in vivo. This study suggests a combination of imaging biomarkers with potential for delineating clinical response to immunotherapy.

Automated summary

Although immune checkpoint blockade therapy has shown remarkable clinical success, its efficacy is limited to a minority of patients and predicting treatment response remains challenging. Saida and colleagues utilized advanced molecular imaging modalities to study changes in the tumor microenvironment that correlate with response to immune checkpoint blockade therapy, offering potential imaging biomarkers for assessing clinical response to immunotherapy.